Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Ítems similars

• Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
  per: Jasielec, Jagoda K., et al.
  Publicat: (2020)
• Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
  per: Dytfeld, Dominik, et al.
  Publicat: (2014)
• Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
  per: Dimopoulos, M A, et al.
  Publicat: (2017)
• Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
  per: Jakubowiak, Andrzej J., et al.
  Publicat: (2019)
• Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
  per: Mele, Giuseppe, et al.
  Publicat: (2018)